Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Neurology

What Causes CIDP, and Can Infections or Vaccines Trigger It?

At a Glance

CIDP usually has no single known cause. Although some people report an infection or vaccination shortly before symptoms begin, current evidence does not prove that common infections or routine vaccines cause CIDP; discuss vaccine decisions with your clinician.

In this answer

2 sections

01

The Role of Infections and Vaccines

02

When to Suspect Another Illness or Cause

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired, immune-mediated disorder. This means the body’s immune system mistakenly attacks the protective covering of the peripheral nerves, known as the myelin sheath [1]. The specific cause is usually unknown; genetic susceptibility and various immune or environmental contributors are currently being studied [2]. CIDP is not an infection itself, and it is not contagious—you cannot catch it from or pass it to anyone else [3][1].

The Role of Infections and Vaccines

Many patients wonder if a recent illness, infection, or vaccination triggered their CIDP. In studies looking back at cohorts of CIDP patients, roughly 9% to 12% reported having a respiratory or gastrointestinal infection in the six weeks before their symptoms started, and about 1% to 1.5% had a recent vaccination [4][5].

However, it is crucial to distinguish a temporal association (two things happening close together in time) from causation (one thing physically causing the other). Because infections and routine vaccinations are very common in the general population, the fact that they occurred before CIDP onset does not prove they caused the disease [4][6][7]. The studies reporting these percentages did not compare CIDP patients to healthy individuals, so they do not prove that an infection or vaccine increases your overall risk of developing the disease [4][8].

While certain infections are a firmly established trigger for Guillain-Barré syndrome (GBS)—a related but acute nerve condition—no consistent causal association has been established for infections or routine vaccines causing new-onset CIDP [9][4]. While rare post-vaccination cases of CIDP have been reported, the available evidence does not prove causation [7][10]. You should not stop, delay, or avoid future vaccines without first discussing the individual risks and benefits with your neurologist and primary care clinician [11].

⚠️ URGENT CARE WARNING: If you experience rapidly worsening weakness, an inability to walk, or trouble breathing, swallowing, speaking, or handling secretions, seek emergency medical care immediately. Do not wait for a routine neurology appointment, as these can be signs of a medical emergency like Guillain-Barré syndrome (GBS) [12].

When to Suspect Another Illness or Cause

CIDP can be difficult to diagnose and is sometimes confused with other neuropathies [13]. When nerve symptoms appear suddenly, doctors must carefully evaluate whether the diagnosis is typical CIDP or another condition [12].

  • Guillain-Barré Syndrome (GBS) vs. Acute-onset CIDP: GBS typically reaches its worst point within four weeks, whereas typical CIDP progresses over at least eight weeks [14]. However, this timeline is a diagnostic clue, not an absolute rule. Acute-onset CIDP can initially look exactly like GBS, but continues to worsen or relapse over time [15]. Diagnosis depends on physical examination, nerve-conduction studies, and how the condition responds to treatment [16].
  • Medication-Induced Neuropathy: Certain medications, such as tumor necrosis factor (TNF) blockers used to treat autoimmune diseases, have been associated with CIDP-like nerve damage [17][18]. Always review your entire medication history with your neurologist. Do not stop any prescribed medicine on your own without consulting your doctor.
  • Other Medical Conditions: Diabetes, monoclonal gammopathies/plasma-cell disorders (such as POEMS syndrome, a rare blood disorder), and amyloidosis (a rare condition where abnormal proteins build up in tissues) can cause nerve damage that mimics CIDP [19][20][21].
  • Autoimmune Nodopathies: These are a recently recognized, distinct group of antibody-mediated nerve disorders [22]. Instead of targeting the myelin itself, specific antibodies attack proteins (like neurofascin-155 or contactin-1) located at the nodes of Ranvier—the tiny gaps between myelin segments [23]. Because these disorders may respond differently to standard CIDP therapies, specialists may selectively order antibody testing if your clinical pattern is unusual or if you do not respond well to initial treatments [23].

Common questions in this guide

What is the usual cause of CIDP?
CIDP happens when the immune system mistakenly attacks myelin, the protective covering around peripheral nerves. In most people, the exact reason this immune attack starts is unknown; genetic, immune, and environmental influences are being studied. CIDP is not an infection and cannot be passed between people.
Can an infection lead to CIDP?
Some people with CIDP report a respiratory or stomach infection in the six weeks before symptoms begin. However, studies have not shown that these infections cause CIDP or increase a person's overall risk. Infections are a well-established trigger for Guillain-Barré syndrome, a related but usually sudden nerve disorder, not for new-onset CIDP.
Can a vaccine cause CIDP?
Rare cases of CIDP have been reported after vaccination, but the available evidence does not prove that routine vaccines cause CIDP. Because infections and vaccinations are common, occurring before symptoms does not by itself establish cause. Do not skip or delay future vaccines without discussing your personal risks and benefits with your neurologist and primary care clinician.
How do doctors tell CIDP apart from Guillain-Barré syndrome?
Guillain-Barré syndrome typically reaches its worst point within four weeks, while typical CIDP progresses over at least eight weeks. A form called acute-onset CIDP can initially look like Guillain-Barré syndrome, so doctors also consider the examination, nerve-conduction studies that measure how signals travel through nerves, continued worsening or relapses, and response to treatment.
What other conditions can look like CIDP?
Diabetes, certain blood-protein disorders such as POEMS syndrome, amyloidosis, and some medication-related nerve injuries can resemble CIDP. Autoimmune nodopathies are different antibody-related nerve disorders that affect proteins at the nodes of Ranvier, the tiny gaps between myelin segments, and may require specialized testing when symptoms are unusual or initial treatment does not help.
When does weakness with possible CIDP require emergency care?
Seek emergency care for rapidly worsening weakness, inability to walk, or trouble breathing, swallowing, speaking, or handling saliva and other secretions. These symptoms can signal a medical emergency such as Guillain-Barré syndrome and should not wait for a routine neurology appointment.

Related questions

How Long Does It Take to Recover from CIDP Treatment? How Common Is CIDP, and Who Is Most Likely to Get It? Is Nerve Damage From CIDP Permanent or Reversible? Can You Eventually Stop CIDP Treatment and Reach Remission? NF155, CNTN1 & CASPR1: What Do They Mean for Treatment?
Show more
How Does CIDP Differ From Diabetic Neuropathy? Explained What Blood Tests Are Recommended for Suspected CIDP? What Is the IVIG Wear-Off Effect in CIDP Treatment? Why Is a Lumbar Puncture Needed to Help Diagnose CIDP? How Is CIDP Different From ALS, CMT, MMN, and POEMS? Can CIDP Cause One-Sided Symptoms? MADSAM Explained What Is the Difference Between Anti-MAG Neuropathy and CIDP? How CIDP Variants Affect Your Treatment and Prognosis What Should You Do If IVIg or Steroids Fail for CIDP? Autoimmune Nodopathies vs CIDP: What Are the Symptoms? Does CIDP Shorten Life Expectancy? Prognosis Explained Why Is Physical Therapy Important for CIDP Recovery? How Does Efgartigimod (Vyvgart) Work for CIDP Treatment? Is CIDP Hereditary or Contagious? Passing It to Children How Is CIDP Diagnosed and How Long Does Diagnosis Take? Can You Have CIDP With a Borderline or Normal Nerve Study? Can MRI or Ultrasound Diagnose CIDP When Tests Are Unclear? How Do Doctors Distinguish Acute-Onset CIDP From GBS? When Should CIDP, Anti-MAG, or Protein Tests Be Done? Do I Need a Nerve Biopsy or Genetic Test for CIDP? Can You Have CIDP Without Muscle Weakness? Explained

Get notified when new evidence is published on Chronic inflammatory demyelinating polyneuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (23)
  1. 1

    Myokymia in a Patient with Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

    Gangula PKRP, Samarla PK, Krishnasamy MJ, et al.

    The Journal of the Association of Physicians of India 2023; (71(12)):100-101 doi:10.59556/japi.71.0408.

    PMID: 38736063
  2. 2

    The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies.

    Querol LA, Hartung HP, Lewis RA, et al.

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2022; (19(3)):864-873 doi:10.1007/s13311-022-01221-y.

    PMID: 35378684
  3. 3

    Novel Immunological and Therapeutic Insights in Guillain-Barré Syndrome and CIDP.

    Querol L, Lleixà C

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2021; (18(4)):2222-2235 doi:10.1007/s13311-021-01117-3.

    PMID: 34549385
  4. 4

    Antecedent infections and vaccinations in chronic inflammatory demyelinating polyneuropathy: A European collaborative study.

    Rajabally YA, Peric S, Bozovic I, et al.

    Muscle & nerve 2021; (64(6)):657-661 doi:10.1002/mus.27374.

    PMID: 34263956
  5. 5

    Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Italian CIDP Database.

    Doneddu PE, Bianchi E, Cocito D, et al.

    European journal of neurology 2020; (27(1)):136-143 doi:10.1111/ene.14044.

    PMID: 31325350
  6. 6

    Chronic Inflammatory Demyelinating Polyneuropathy Following Natural Influenza A Infection in a Pediatric Patient: A Case Report and Literature Review.

    Grew E, Gianneschi G, Elgallab J

    Case reports in neurological medicine 2025; (2025()):8840308 doi:10.1155/crnm/8840308.

    PMID: 40365113
  7. 7

    Inflammatory demyelinating polyneuropathy after the ChAdOx1 nCoV-19 vaccine may follow a chronic course.

    de Souza A, Oo WM, Giri P

    Journal of the neurological sciences 2022; (436()):120231 doi:10.1016/j.jns.2022.120231.

    PMID: 35313224
  8. 8

    Epidemiology of chronic inflammatory demyelinating polyradiculoneuropathy in The Netherlands.

    Broers MC, de Wilde M, Lingsma HF, et al.

    Journal of the peripheral nervous system : JPNS 2022; (27(3)):182-188 doi:10.1111/jns.12502.

    PMID: 35567759
  9. 9

    Acute/chronic inflammatory polyradiculoneuropathy.

    Miranda C, Brannagan TH

    Handbook of clinical neurology 2023; (195()):619-633 doi:10.1016/B978-0-323-98818-6.00026-1.

    PMID: 37562890
  10. 10

    Chronic inflammatory demyelinating polyneuropathy after SARS-CoV2 vaccination: update of the literature and patient characterization.

    Ginanneschi F, Vinciguerra C, Volpi N, et al.

    Immunologic research 2023; (71(6)):833-838 doi:10.1007/s12026-023-09406-z.

    PMID: 37395901
  11. 11

    Two Case Reports of Chronic Inflammatory Demyelinating Polyneuropathy After COVID-19 Vaccination.

    Kim S, Lee EK, Sohn E

    Journal of Korean medical science 2023; (38(8)):e57 doi:10.3346/jkms.2023.38.e57.

    PMID: 36852853
  12. 12

    Acute-onset chronic inflammatory demyelinating polyneuropathy with cranial nerves and respiratory tract involvement: A case report.

    Mansour M, Ouerdiene A, Bedoui I, et al.

    Clinical case reports 2020; (8(11)):2199-2203 doi:10.1002/ccr3.3087.

    PMID: 33235757
  13. 13

    CIDP diagnostic pitfalls and perception of treatment benefit.

    Allen JA, Lewis RA

    Neurology 2015; (85(6)):498-504 doi:10.1212/WNL.0000000000001833.

    PMID: 26180143
  14. 14

    Autoimmune neuropathies: New guidelines and expert insights into clinical decision making.

    van Doorn PA, Sommer C, Rajabally YA

    Journal of the neurological sciences 2025; (479()):125659 doi:10.1016/j.jns.2025.125659.

    PMID: 41308579
  15. 15

    [Acute-Onset Chronic Inflammatory Demyelinating Polyradiculoneuropathy].

    Kanbayashi T, Sonoo M

    Brain and nerve = Shinkei kenkyu no shinpo 2015; (67(11)):1388-96 doi:10.11477/mf.1416200311.

    PMID: 26560954
  16. 16

    Misdiagnosis and diagnostic pitfalls of chronic inflammatory demyelinating polyradiculoneuropathy.

    Broers MC, Bunschoten C, Drenthen J, et al.

    European journal of neurology 2021; (28(6)):2065-2073 doi:10.1111/ene.14796.

    PMID: 33657260
  17. 17

    Bilateral facial nerve palsies secondary to chronic inflammatory demyelinating polyneuropathy following adalimumab treatment.

    Yao A, Chan H, Macdonell RAL, et al.

    Clinical neurology and neurosurgery 2018; (164()):64-66 doi:10.1016/j.clineuro.2017.11.001.

    PMID: 29179036
  18. 18

    Infliximab induced chronic inflammatory demyelinating polyneuropathy: a case report.

    Karantali E, Katsikaki G, Chatzikonstantinou S, Papagiannopoulos S

    Hippokratia 2019; (23(4)):179-180.

    PMID: 32742170
  19. 19

    The overlap of diabetic and inflammatory neuropathies: Epidemiology, possible mechanisms, and treatment implications.

    Rajabally YA, Min YG

    Clinical neurology and neurosurgery 2025; (249()):108719 doi:10.1016/j.clineuro.2025.108719.

    PMID: 39798331
  20. 20

    Paraproteinemia and neuropathy.

    Koike H, Katsuno M

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021; (42(11)):4489-4501 doi:10.1007/s10072-021-05583-7.

    PMID: 34529193
  21. 21

    Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.

    Adams D, Ando Y, Beirão JM, et al.

    Journal of neurology 2021; (268(6)):2109-2122 doi:10.1007/s00415-019-09688-0.

    PMID: 31907599
  22. 22

    Distinguish CIDP with autoantibody from that without autoantibody: pathogenesis, histopathology, and clinical features.

    Tang L, Huang Q, Qin Z, Tang X

    Journal of neurology 2021; (268(8)):2757-2768 doi:10.1007/s00415-020-09823-2.

    PMID: 32266541
  23. 23

    Autoimmune nodopathies, an emerging diagnostic category.

    Martín-Aguilar L, Lleixà C, Pascual-Goñi E

    Current opinion in neurology 2022; (35(5)):579-585 doi:10.1097/WCO.0000000000001107.

    PMID: 35989582

This page is for informational purposes only and does not constitute medical advice. Discuss suspected CIDP triggers, medication changes, and vaccination decisions with your neurologist or primary care clinician.